Understanding Single-Pass Tangential Flow Filtration and the New Era of Bioprocessing

Single-pass tangential flow filtration (SPTFF) technology from Pall Corporation is revolutionizing current and future
bioprocessing platforms with its implementations in biotech, vaccine and plasma industries. Its features are
protected by a portfolio of patents[1-6]. Common applications of the Cadence™ SPTFF technology extend to but
are not limited to inline volume reduction and/or concentration, in-process dilution/de-salting, high concentration
formulations, and processing of fragile molecules. In this context, SPTFF technology is not only an important
addition to the process development tool-box for platform process evaluation but also a crucial enabler of
integrated, streamlined and continuous bioprocessing initiatives.

Within the diverse filtration portfolio of Pall Life Sciences, this breakthrough technology is made available in a
variety of building blocks that utilize different membrane types and configurations to provide a comprehensive
solution package that will meet end-user’s processing needs and targets over wide range of applications[7-17].
For example, Cadence Inline Concentrator (ILC) modules are holder-less SPTFF devices equipped with a
built-in fixed retentate restrictor, which greatly simplifies SPTFF process control and achieves high conversion
separations with the simplicity of direct flow filtration.